Ranibizumab is a biologic medicine used to treat age-related macular degeneration (AMD), a common condition that affects the central vision. Ranibizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), a protein that stimulates the growth of new blood vessels in the eye. By stopping the growth of these blood vessels, Ranibizumab helps to reduce the swelling and fluid buildup that can cause vision loss in AMD. Ranibizumab is often used in combination with other treatments such as photocoagulation and photodynamic therapy.
Ranibizumab, marketed under the brand name Lucentis, is a medication used to treat various eye diseases characterized by abnormal blood vessel growth [1, 2]. Here's a breakdown of its mechanism of action and applications:
Type of drug:
- VEGF-A inhibitor: Ranibizumab belongs to a class of drugs called vascular endothelial growth factor A (VEGF-A) inhibitors [1, 2].
How it works:
- Targets VEGF-A: Ranibizumab is a humanized monoclonal antibody designed to specifically target VEGF-A, a protein that promotes the growth of new blood vessels [1, 2].
- Inhibits blood vessel growth: By binding to VEGF-A, Ranibizumab prevents it from stimulating the formation of new blood vessels in the eye. This is crucial because abnormal blood vessel growth can contribute to vision problems.
- Reduces fluid leakage: Abnormal blood vessels can also leak fluid, leading to swelling in the eye. Ranibizumab helps reduce this leakage, potentially improving vision [2].
Conditions treated:
- Wet age-related macular degeneration (AMD): This is a condition where abnormal blood vessels grow behind the macula, the central part of the retina responsible for sharp central vision [1, 2].
- Macular edema following retinal vein occlusion (RVO): RVO is a blockage of a vein in the retina, which can lead to fluid buildup and swelling in the macula [1, 2].
- Diabetic macular edema (DME): This is a complication of diabetes that causes swelling in the macula due to leaking blood vessels [1, 2].
- Myopic choroidal neovascularization (mCNV): This is a condition where abnormal blood vessels grow under the macula in people with nearsightedness (myopia) [2].
Benefits:
- May improve or maintain vision in patients with the above eye diseases [1, 2].
- Minimizes fluid leakage and swelling in the macula [2].
Important to consider:
- Requires injection into the eye: Ranibizumab is administered through an injection into the vitreous cavity of the eye by a qualified healthcare professional [1, 2].
- Multiple injections might be needed: Depending on the condition and response to treatment, a series of injections may be necessary [1, 2].
- Can cause side effects: Common side effects include eye pain, bleeding in the eye, and infection [2].
- Not a cure: Ranibizumab helps manage these eye diseases but doesn't cure them [1, 2].
- Regular monitoring is crucial: Your doctor will monitor your vision and eye health regularly while receiving Ranibizumab treatment [2].